Floatz logo

Silevertinib

Epidermal Growth Factor Receptor C797S

Black Diamond Therapeutics, Inc.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Epidermal Growth Factor Receptor C797S cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Silevertinib is also rated in:

GBMDormant
B
Indicative ·
60 / 100
View asset →
central nervous system disorderDormant
CCC
Indicative ·
53 / 100
View asset →
brain cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →